Last reviewed · How we verify
NCT05199948
Weight, Energy, Lipids, and the Liver (WELL) Study
NA trial testing Soybean Oil Foods in Nonalcoholic Fatty Liver in 74 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2025
Quick facts
| Lead sponsor | Ohio State University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 74 |
| Start date | 2 May 2022 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Soybean Oil Foods
- Palm Oil Foods
Conditions studied
- Nonalcoholic Fatty Liver — all drugs for Nonalcoholic Fatty Liver →
Sponsor
Ohio State University
Who can join
Adults 22 to 80, any sex, with Nonalcoholic Fatty Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The research study is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in hepatic lipid accumulation, visceral adipose tissue and postprandial lipid, markers of inflammation and energy metabolism in participants who consume 3 study foods per day for 16 week, while maintaining their body weight.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05199948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Soybean Oil Foods
Trials testing the same drug.
- NCT04975763 — Dietary Oils to Sustain Energy Study · NA · active not recruiting
Other recruiting trials for Nonalcoholic Fatty Liver
Currently open trials in the same condition.
- NCT07007741 — Digital Therapy for Fatty Liver Disease · NA · recruiting
- NCT04595474 — Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes · active not recruiting
- NCT05165706 — Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance · NA · recruiting
Other Ohio State University trials
Trials by the same sponsor.
- NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
- NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
- NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
- NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
- NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05199948 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05199948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing